{"id":"ql0911","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QL0911 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"QL0911 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:49.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07455006","phase":"PHASE3","title":"Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-20","conditions":"Thrombocytopenia, Immune","enrollment":60},{"nctId":"NCT06456528","phase":"PHASE2, PHASE3","title":"QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-22","conditions":"Cancer Treatment-Induced Thrombocytopenia","enrollment":235},{"nctId":"NCT05554913","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-11-08","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":63},{"nctId":"NCT05851027","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-01-15","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":50},{"nctId":"NCT05621330","phase":"PHASE3","title":"Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-10-18","conditions":"Primary Immune Thrombocytopenia","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QL0911","genericName":"QL0911","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QL0911 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}